Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.54 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 4/20 | 0.47 |
| ▸ | GCGR | P47871 | 3/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697025 | 0.89 | CALCR (0.51) | CALCRCRHR1CRHR2KEAP1GLP1R | |
| SCHEMBL30358158 | 0.88 | CALCR (0.57) | CALCRCRHR1CRHR2KEAP1GLP1R | |
| SCHEMBL30772230 | 0.88 | CALCR (0.60) | CALCRCRHR1CRHR2KEAP1GLP1R | |
| SCHEMBL30640317 | 0.88 | CALCR (0.53) | CALCRCRHR1CRHR2KEAP1GLP1R | |
| SCHEMBL30576976 | 0.87 | GLP1R (0.56) | CALCRCRHR1CRHR2GLP1R | |
| SCHEMBL31307277 | 0.86 | EGFR (0.47) | CALCRCRHR1CRHR2KEAP1GLP1R | |
| SCHEMBL31182576 | 0.85 | PTH1R (0.58) | CALCRCRHR1CRHR2GLP1RGCGR | |
| SCHEMBL30712931 | 0.85 | CALCR (0.63) | CALCRCRHR1CRHR2GLP1R | |
| SCHEMBL30436887 | 0.84 | CALCR (0.55) | CALCRCRHR1CRHR2GLP1RGCGR | |
| SCHEMBL31656529 | 0.84 | CALCR (0.62) | CALCRCRHR1CRHR2GLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| CN-119792492-A | Application of irisin in preparation of prion medicament | 中国农业大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-119792259-A | Application of idebenone in preparation of prion disease medicines | 中国农业大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-114369115-A | A pair of PrP106-126Chiral phospholipid with aggregation inhibition effect | 中国科学院大连化学物理研究所 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369115-A | A pair of PrP106-126Chiral phospholipid with aggregation inhibition effect | 中国科学院大连化学物理研究所 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369115-A | A pair of PrP106-126Chiral phospholipid with aggregation inhibition effect | 中国科学院大连化学物理研究所 | 2022-04-19 | — | — | CN | disclosed |
| US-20220105088-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSON, ANXIETY, AND NEURODEGENERATIVE DISORDERS | AVANIR PHARMACEUTICALS INC (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105088-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSON, ANXIETY, AND NEURODEGENERATIVE DISORDERS | CHRNA6, ACHE, DRD2 | CALCR 2224/4885CRHR1 287/4885CRHR2 847/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | CALCR 321/4885CRHR1 1355/4885CRHR2 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.